Eur Rev Med Pharmacol Sci 2014; 18 (20): 2982-
DOI:

Association between bevacizumab-related chemotherapy regimens and serum vascular endothelial growth factor-A165b level in patients with metastatic colorectal cancer

L. Xu, C. Chi, C. Wang, L.M. Zhang

The article “Association between bevacizumab-related chemotherapy regimens and serum vascular endothelial growth factor-A165b level in patients with metastatic colorectal cancer” by L. Xu, C. Chi, C. Wang, L.M. Zhang, published in Eur Rev Med Pharmacol Sci 2014;  18 (18): 2687-2692 has been withdrawn.

The Publisher apologizes for any inconvenience this may cause.

To cite this article

L. Xu, C. Chi, C. Wang, L.M. Zhang
Association between bevacizumab-related chemotherapy regimens and serum vascular endothelial growth factor-A165b level in patients with metastatic colorectal cancer

Eur Rev Med Pharmacol Sci
Year: 2014
Vol. 18 - N. 20
Pages: 2982-
DOI:

Keywords Related articles:

  1. Association between bevacizumab-related chemotherapy regimens and serum vascular endothelial growth factor-A165b level in patients with metastatic colorectal cancer
  2. Clinical significance of a new oncogenic factor P5CR1 in gastric cancer
  3. Targeting TGF-β1 and AKT signal on growth and metastasis of anaplastic thyroid cancer cell in vivo
  4. Prognostic value of serum Tie-2 and vascular endothelial growth factor levels in cancer patients
  5. Association of disease condition with changes in intestinal flora, and plasma endotoxin and vascular endothelial growth factor levels in patients with liver cancer